Summary

Amid the rapidly evolving biomedical diagnostics landscape, the Asia-Pacific (APAC) region has emerged as a fertile ground for transformative molecular techniques such as In Situ Hybridization (ISH). Valued at approximately USD 0.48 billion in 2024, the APAC ISH market is poised to flourish at a remarkable CAGR of 15.40% between 2025 and 2035, driven by accelerating investments in oncology research, precision medicine, and increasing healthcare spending across major APAC economies. ISH is an advanced cytogenetic tool used to detect specific nucleic acid sequences within tissue sections, enabling localization of DNA or RNA targets at the cellular level. Its ability to provide spatial and molecular insights in complex biological samples has revolutionized diagnostics, especially in cancer and infectious diseases. As public and private sector entities across APAC push toward enhanced pathology infrastructure and molecular testing, the market for in situ hybridization is expanding its footprint.
The surging incidence of chronic and rare diseases in the region, coupled with the growing demand for spatial genomics, is amplifying the adoption of DNA FISH, RNA FISH, and CISH technologies in clinical and research settings. The introduction of AI-enhanced imaging platforms and digitized pathology solutions has further empowered laboratories to integrate ISH workflows with next-generation analytics. Furthermore, pharmaceutical and biotech firms are heavily investing in ISH-based companion diagnostics to facilitate targeted therapy selection—especially in oncology, where gene fusion detection and expression profiling have become central to treatment decisions. According to WHO, cancer incidence in Asia is projected to rise by over 40% by 2040, amplifying the need for sophisticated diagnostics. These dynamics are reshaping ISH as not just a laboratory technique, but a critical enabler of precision health across APAC.
In regional terms, China, Japan, and India represent high-growth territories owing to their booming biotechnology industries, increasing clinical trial activity, and widespread adoption of genomics-based diagnostics. China leads with strong government-backed R&D frameworks and aggressive expansion of molecular laboratories. Meanwhile, Japan has been at the forefront of ISH innovation, driven by an aging population and a proactive regulatory stance toward advanced diagnostics. India is emerging rapidly as a cost-effective manufacturing hub for ISH reagents and instruments while ramping up healthcare digitization initiatives. Elsewhere, South Korea and Australia are seeing promising uptake, supported by academic excellence and public health programs emphasizing early cancer detection. Despite infrastructural disparities across emerging ASEAN nations, the region as a whole reflects a compelling growth narrative propelled by policy support, awareness campaigns, and public-private partnerships.
Major market players included in this report are:
• Agilent Technologies
• BioGenex
• Thermo Fisher Scientific
• Merck KGaA
• Leica Biosystems (Danaher)
• Bio-Techne Corporation
• Abbott Laboratories
• PerkinElmer Inc.
• F. Hoffmann-La Roche Ltd
• Advanced Cell Diagnostics
• Biocare Medical, LLC
• NeoGenomics Laboratories
• QIAGEN
• Enzo Life Sciences
• Genemed Biotechnologies Inc.
Global APAC In Situ Hybridization Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period - 2025-2035
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analysts’ working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players.
The detailed segments and sub-segments of the market are explained below:
By Products:
• Consumables
• Instruments
• Software
By Technology:
• DNA FISH
• RNA FISH
• PNA FISH
• CISH
By Application:
• Cancer
• Immunology
• Neuroscience
• Cytology
By End-user:
• Hospitals
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations (CROs)
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1. Global APAC In Situ Hybridization Market Report Scope & Methodology
1.1. Research Objective
1.2. Research Methodology
1.2.1. Forecast Model
1.2.2. Desk Research
1.2.3. Top Down and Bottom-Up Approach
1.3. Research Attributes
1.4. Scope of the Study
1.4.1. Market Definition
1.4.2. Market Segmentation
1.5. Research Assumption
1.5.1. Inclusion & Exclusion
1.5.2. Limitations
1.5.3. Years Considered for the Study
Chapter 2. Executive Summary
2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. Key Findings
Chapter 3. Global APAC In Situ Hybridization Market Forces Analysis (2024–2035)
3.1. Market Forces Shaping The Global APAC In Situ Hybridization Market (2024–2035)
3.2. Drivers
3.2.1. Rising cancer incidence and demand for early-stage diagnostics
3.2.2. Advancements in AI-enhanced pathology and spatial genomics
3.2.3. Increased government and private investments in precision medicine
3.3. Restraints
3.3.1. High cost of ISH instrumentation and consumables
3.3.2. Lack of skilled workforce and standardization challenges
3.4. Opportunities
3.4.1. Growing integration of ISH with digital pathology and companion diagnostics
3.4.2. Emerging biotechnology infrastructure across ASEAN & South Asia
Chapter 4. Global APAC In Situ Hybridization Industry Analysis
4.1. Porter’s 5 Forces Model
4.1.1. Bargaining Power of Buyer
4.1.2. Bargaining Power of Supplier
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Forecast Model (2024–2035)
4.3. PESTEL Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top Investment Opportunities
4.5. Top Winning Strategies (2025)
4.6. Market Share Analysis (2024–2025)
4.7. Global Pricing Analysis and Trends (2025)
4.8. Analyst Recommendation & Conclusion
Chapter 5. Global APAC In Situ Hybridization Market Size & Forecasts by Product 2025–2035
5.1. Market Overview
5.2. Consumables
5.2.1. Top Countries Breakdown Estimates & Forecasts, 2025–2035
5.2.2. Market Size Analysis, by Region, 2025–2035
5.3. Instruments
5.3.1. Top Countries Breakdown Estimates & Forecasts, 2025–2035
5.3.2. Market Size Analysis, by Region, 2025–2035
5.4. Software
5.4.1. Top Countries Breakdown Estimates & Forecasts, 2025–2035
5.4.2. Market Size Analysis, by Region, 2025–2035
Chapter 6. Global APAC In Situ Hybridization Market Size & Forecasts by Technology 2025–2035
6.1. Market Overview
6.2. DNA FISH
6.2.1. Top Countries Breakdown Estimates & Forecasts, 2025–2035
6.2.2. Market Size Analysis, by Region, 2025–2035
6.3. RNA FISH
6.3.1. Top Countries Breakdown Estimates & Forecasts, 2025–2035
6.3.2. Market Size Analysis, by Region, 2025–2035
6.4. PNA FISH
6.4.1. Top Countries Breakdown Estimates & Forecasts, 2025–2035
6.4.2. Market Size Analysis, by Region, 2025–2035
6.5. CISH
6.5.1. Top Countries Breakdown Estimates & Forecasts, 2025–2035
6.5.2. Market Size Analysis, by Region, 2025–2035
Chapter 7. Global APAC In Situ Hybridization Market Size & Forecasts by Application 2025–2035
7.1. Market Overview
7.2. Cancer
7.3. Immunology
7.4. Neuroscience
7.5. Cytology
Chapter 8. Global APAC In Situ Hybridization Market Size & Forecasts by End-User 2025–2035
8.1. Hospitals
8.2. Pharmaceutical Companies
8.3. Biotechnology Companies
8.4. Contract Research Organizations (CROs)
Chapter 9. Global APAC In Situ Hybridization Market Size & Forecasts by Region 2025–2035
9.1. Growth Snapshot – Regional Market Outlook
9.2. Top Leading & Emerging Countries
9.3. North America
9.3.1. U.S.
9.3.2. Canada
9.4. Europe
9.4.1. UK
9.4.2. Germany
9.4.3. France
9.4.4. Spain
9.4.5. Italy
9.4.6. Rest of Europe
9.5. Asia Pacific
9.5.1. China
9.5.2. India
9.5.3. Japan
9.5.4. Australia
9.5.5. South Korea
9.5.6. Rest of Asia Pacific
9.6. Latin America
9.6.1. Brazil
9.6.2. Mexico
9.7. Middle East and Africa
9.7.1. UAE
9.7.2. Saudi Arabia
9.7.3. South Africa
9.7.4. Rest of Middle East & Africa
Chapter 10. Competitive Intelligence
10.1. Top Market Strategies
10.2. Agilent Technologies
10.2.1. Company Overview
10.2.2. Key Executives
10.2.3. Company Snapshot
10.2.4. Financial Performance (Subject to Data Availability)
10.2.5. Product/Services Port
10.2.6. Recent Development
10.2.7. Market Strategies
10.2.8. SWOT Analysis
10.3. BioGenex
10.4. Thermo Fisher Scientific
10.5. Merck KGaA
10.6. Leica Biosystems (Danaher)
10.7. Bio-Techne Corporation
10.8. Abbott Laboratories
10.9. PerkinElmer Inc.
10.10. F. Hoffmann-La Roche Ltd
10.11. Advanced Cell Diagnostics
10.12. Biocare Medical, LLC
10.13. NeoGenomics Laboratories
10.14. QIAGEN
10.15. Enzo Life Sciences
10.16. Genemed Biotechnologies Inc.